• Biotech & Pharmaceuticals
  • Diagnostics, Life Science Tools & Services, & Precision Medicine
  • MedTech
  • Digital Health & Enterprise HIT
  • Investors
Dr. Marcus Koch

Dr. Marcus Koch

Vice President


Allergy & Immunology, CNS Diseases, Oncology, Rare Diseases, Women's Health

Marcus joined Health Advances in 2022. He has over 15 years’ experience in life sciences strategy, commercialization and investing gained in management consulting, the biopharma industry, and investment banking.

Prior to joining Health Advances, he worked as a senior sell-side equity research analyst at UBS Investment Bank, covering European drug and biotech stocks and authoring several widely read thematic research papers on health policy, pharmaceutical market access, pricing and reimbursement for investors. Previously, Marcus held strategic planning, product management and medical affairs strategy leadership roles at Amgen’s international, Swiss, and European organizations, implementing planning and commercial excellence, managing inline and pipeline products and defining the European patient engagement strategy, respectively. He began his career as management consultant and project leader at Bain & Company and Booz & Company, focusing on pharma and healthcare strategy development. His therapeutic area expertise spans onco-hematology, nephrology, osteology, immunology, dermatology, anti-infectives, CNS, and rare diseases.

Marcus is a licensed pharmacist and earned his PhD at Max Planck Institute of Molecular Physiology/TU Dortmund. He completed a university diploma program in healthcare market access at Aix-Marseille University and is a CFA charterholder.

Marcus joined Health Advances in 2022. He has over 15 years’ experience in life sciences strategy, commercialization and investing gained in management consulting, the biopharma industry, and investment banking.

Prior to joining Health Advances, he worked as a senior sell-side equity research analyst at UBS Investment Bank, covering European drug and biotech stocks and authoring several widely read thematic research papers on health policy, pharmaceutical market access, pricing and reimbursement for investors. Previously, Marcus held strategic planning, product management and medical affairs strategy leadership roles at Amgen’s international, Swiss, and European organizations, implementing planning and commercial excellence, managing inline and pipeline products and defining the European patient engagement strategy, respectively. He began his career as management consultant and project leader at Bain & Company and Booz & Company, focusing on pharma and healthcare strategy development. His therapeutic area expertise spans onco-hematology, nephrology, osteology, immunology, dermatology, anti-infectives, CNS, and rare diseases.

Marcus is a licensed pharmacist and earned his PhD at Max Planck Institute of Molecular Physiology/TU Dortmund. He completed a university diploma program in healthcare market access at Aix-Marseille University and is a CFA charterholder.